HuMax-CD20 in Chronic Lymphocytic Leukemia
NCT00093314 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2015-04-21
Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.
Conditions
Interventions
- DRUG
-
HuMax-CD20
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-10-31
- Primary Completion
- 2007-01-31
- Completion
- 2007-01-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
NCT02098967 ·Status: COMPLETED ·Phase: PHASE1
-
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
NCT00006364 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01664897 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
NCT00920140 ·Status: COMPLETED ·Phase: PHASE2
-
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01768897 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Investigation of Clofarabine in Acute Leukemias
NCT00098033 ·Status: COMPLETED ·Phase: PHASE2
-
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
NCT00003997 ·Status: COMPLETED ·Phase: PHASE1
-
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
NCT01751425 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
NCT00644878 ·Status: TERMINATED ·Phase: PHASE2
-
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
NCT04887259 ·Status: TERMINATED ·Phase: PHASE1
-
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
NCT04030195 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
NCT06692803 ·Status: COMPLETED
-
Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer
NCT00387153 ·Status: TERMINATED ·Phase: PHASE1
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
NCT02348957 ·Status: COMPLETED
-
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06489184 ·Status: NOT_YET_RECRUITING
-
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
NCT04665115 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
NCT06629584 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
NCT00660920 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02801578 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2